Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Review

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

         
Total article views   Abstract views HTML views PDF downloads Totals
17,762 Dovepress* 7,451 2,929+ 1,767 10,380
PubMed Central* 0 7,382 1,354 7,382
Totals 7,451 10,311 3,121 17,762
*Since 31 May 2018
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar